Publications

Schwedler, J., Sumner, C.A., Lopez-Cazares, G., Sinha, A., McIlroy, P.R., Light, Y.K., Welborn, D.G., Negrete, O.A., & Harmon, B.N. (2023). A pipeline for discovery & applications for Brain-targeting nanoparticle drug delivery & Engineered therapeutics [Poster]. 10.2172/2431119

Sumner, C.A., Schwedler, J., Stefan, M., Sinha, A., McIlroy, P.R., Light, Y.K., Thatcher, C.E., Kim, C.Y., Weilhammer, D.R., Negrete, O.A., & Harmon, B.N. (2022). Characterization of novel BBB-penetrating nanobodies for delivery of therapeutic cargo to the CNS [Conference Poster]. 10.2172/2588934

le Pham, T., McIlroy, P.R., Sinha, A., Stefan, M.A., Jaryenneh, J.D., Light, Y.K., Weilhammer, D.R., Jones, I.K.A., Sumner, C.A., Anaya, J., Schwedler, J., & Harmon, B.N. (2022). DISCOVERY, DESIGN, AND ENGINEERING OF NANOBODY-BASED THERAPEUTICS FOR SARS-COV-2 [Conference Poster]. 10.2172/2006087

Schwedler, J., Stefan, M., Sinha, A., McIlroy, P.R., Thatcher, C., Kim, C., Weilhammer, D., & Harmon, B.N. (2022). Therapeutic efficacy of a potent anti-VEEV antibody is contingent on humoral and cell-mediated cytotoxic immunity [Conference Poster]. 10.2172/2005942

Sumner, C.A., Schwedler, J., Stefan, M., Sinha, A., McIlroy, P.R., Thatcher, C., Kim, C.Y., Weilhammer, D.R., Negrete, O.A., & Harmon, B.N. (2022). Characterization of SNL identified BBB-penetrating moieties (BBB PMs) for delivery of therapeutic cargo to the CNS [Conference Poster]. 10.2172/2006120

Lund, S., Collete, N., Sinha, A., Welborn, D.G., Mosesso, R., Schwedler, J., Schoeniger, J.S., & Negrete, O.A. (2022). Imaging in vivo Lipid Nanoparticle Delivery [Conference Poster]. 10.2172/2003836

Lund, S., Collette, N., Sinha, A., Welborn, D.G., Mosesso, R., Schwedler, J., Schoeniger, J.S., & Negrete, O.A. (2022). Imaging and Efficacy of in vivo Lipid Nanoparticle Delivery in Genome Editing [Conference Poster]. 10.2172/2003928

Collette, N., Dhungel, P., Lund, S., Schwedler, J., Freiberg, A., Schoeniger, J.S., & Negrete, O.A. (2022). NSVconferencePoster.ONegrete [Conference Poster]. 10.2172/2003487

Harmon, B.N., le Pham, T., McIlroy, P.R., Sinha, A., Jaryenneh, J.D., Light, Y.K., Schwedler, J., & Stefan, M. (2022). DISCOVERY, DESIGN, AND ENGINEERING OF NANOBODY-BASED THERAPEUTICS FOR SARS-COV-2 [Conference Poster]. 10.2172/2003517

Collette, N., Dhungel, P., Lund, S., Schwedler, J., Saada, E.A., Sinha, A., Light, Y.K., Schoeniger, J.S., & Negrete, O.A. (2021). Immunocompromised Cas9 transgenic mice for rapid in vivo assessment of host factors involved in highly pathogenic virus infection. Molecular Therapy Methods and Clinical Development, 23, pp. 286-295. https://doi.org/10.1016/j.omtm.2021.09.012

Stefan, M., Harmon, B.N., & Schwedler, J. (2021). Protein Display to Discover and Engineer Viral Neutralizing Antibodies [Presentation]. https://www.osti.gov/biblio/1876591

Stefan, M., Light, Y.K., Schwedler, J., Weilhammer, D.R., & Harmon, B.N. (2021). Development of Potent and Effective SARS-CoV-2 Neutralizing Nanobodies [Conference Poster]. 10.2172/1861025

Stefan, M., Schwedler, J., Harmon, B.N., Weilhammer, D., & Diamond, M. (2019). Development of Blood Brain Barrier Penetrating Antibody Therapeutics for Encephalitic Alphaviruses [Conference Poster]. https://www.osti.gov/biblio/1643418

Harmon, B.N., Stefan, M., Schwedler, J., Weilhammer, D., Kafai, N., & Diamond, M. (2019). Development of Blood Brain Barrier Penetrating Antibody Therapeutics for Encephalitic Alphaviruses [Conference Poster]. https://www.osti.gov/biblio/1643345

Friedberg, N., Schwedler, J., Stefan, M., & Harmon, B.N. (2019). Characterizing differential expression of transmembrane protein 30A [Conference Poster]. https://www.osti.gov/biblio/1641259